vs
ASP Isotopes Inc.（ASPI）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
Xtant Medical Holdings, Inc.的季度营收约是ASP Isotopes Inc.的1.9倍（$32.4M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 2.7%），Xtant Medical Holdings, Inc.自由现金流更多（$5.0M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
ASPI vs XTNT — 直观对比
营收规模更大
XTNT
是对方的1.9倍
$16.7M
营收增速更快
ASPI
高出1293.0%
2.7%
自由现金流更多
XTNT
多$52.4M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $32.4M |
| 净利润 | — | $57.0K |
| 毛利率 | 12.5% | 54.9% |
| 营业利润率 | — | -2.9% |
| 净利率 | — | 0.2% |
| 营收同比 | 1295.7% | 2.7% |
| 净利润同比 | -586.8% | 101.8% |
| 每股收益（稀释后） | — | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIXTNT
| Q4 25 | $16.7M | $32.4M | ||
| Q3 25 | $4.9M | $33.3M | ||
| Q2 25 | — | $35.4M | ||
| Q1 25 | — | $32.9M | ||
| Q4 24 | — | $31.5M | ||
| Q3 24 | — | $27.9M | ||
| Q2 24 | — | $29.9M | ||
| Q1 24 | — | $27.9M |
净利润ASPIXTNT
| Q4 25 | — | $57.0K | ||
| Q3 25 | $-12.9M | $1.3M | ||
| Q2 25 | — | $3.5M | ||
| Q1 25 | — | $58.0K | ||
| Q4 24 | — | $-3.2M | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | — | $-3.9M | ||
| Q1 24 | — | $-4.4M |
毛利率ASPIXTNT
| Q4 25 | 12.5% | 54.9% | ||
| Q3 25 | 8.7% | 66.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | — | 62.1% | ||
| Q1 24 | — | 62.1% |
营业利润率ASPIXTNT
| Q4 25 | — | -2.9% | ||
| Q3 25 | -306.1% | 7.6% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | — | -13.5% | ||
| Q2 24 | — | -9.8% | ||
| Q1 24 | — | -12.4% |
净利率ASPIXTNT
| Q4 25 | — | 0.2% | ||
| Q3 25 | -263.7% | 3.9% | ||
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | -10.0% | ||
| Q3 24 | — | -18.0% | ||
| Q2 24 | — | -12.9% | ||
| Q1 24 | — | -15.8% |
每股收益（稀释后）ASPIXTNT
| Q4 25 | — | $0.00 | ||
| Q3 25 | $-0.15 | $0.01 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $17.1M |
| 总债务越低越好 | $14.4M | $11.0M |
| 股东权益账面价值 | $204.2M | $51.0M |
| 总资产 | $498.0M | $94.1M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资ASPIXTNT
| Q4 25 | $333.3M | $17.1M | ||
| Q3 25 | $113.9M | $10.4M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | — | $4.5M |
总债务ASPIXTNT
| Q4 25 | $14.4M | $11.0M | ||
| Q3 25 | $13.9M | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益ASPIXTNT
| Q4 25 | $204.2M | $51.0M | ||
| Q3 25 | $74.1M | $50.4M | ||
| Q2 25 | — | $48.5M | ||
| Q1 25 | — | $43.9M | ||
| Q4 24 | — | $43.0M | ||
| Q3 24 | — | $45.7M | ||
| Q2 24 | — | $45.0M | ||
| Q1 24 | — | $47.7M |
总资产ASPIXTNT
| Q4 25 | $498.0M | $94.1M | ||
| Q3 25 | $225.9M | $106.3M | ||
| Q2 25 | — | $103.5M | ||
| Q1 25 | — | $95.8M | ||
| Q4 24 | — | $93.8M | ||
| Q3 24 | — | $98.9M | ||
| Q2 24 | — | $95.6M | ||
| Q1 24 | — | $93.9M |
负债/权益比ASPIXTNT
| Q4 25 | 0.07× | 0.22× | ||
| Q3 25 | 0.19× | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $5.0M |
| 自由现金流率自由现金流/营收 | -284.7% | 15.4% |
| 资本支出强度资本支出/营收 | 57.9% | 1.2% |
| 现金转化率经营现金流/净利润 | — | 94.39× |
| 过去12个月自由现金流最近4个季度 | — | $10.2M |
8季度趋势，按日历期对齐
经营现金流ASPIXTNT
| Q4 25 | $-37.8M | $5.4M | ||
| Q3 25 | $-8.9M | $4.6M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $665.0K | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-5.8M |
自由现金流ASPIXTNT
| Q4 25 | $-47.4M | $5.0M | ||
| Q3 25 | $-12.0M | $4.2M | ||
| Q2 25 | — | $910.0K | ||
| Q1 25 | — | $87.0K | ||
| Q4 24 | — | $-7.0K | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $-5.7M | ||
| Q1 24 | — | $-6.5M |
自由现金流率ASPIXTNT
| Q4 25 | -284.7% | 15.4% | ||
| Q3 25 | -245.5% | 12.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | -0.0% | ||
| Q3 24 | — | -13.7% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -23.4% |
资本支出强度ASPIXTNT
| Q4 25 | 57.9% | 1.2% | ||
| Q3 25 | 64.4% | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.8% |
现金转化率ASPIXTNT
| Q4 25 | — | 94.39× | ||
| Q3 25 | — | 3.53× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
